Retifanlimab Plus Carboplatin and Paclitaxel Offers PFS Benefit in Recurrent/Metastatic SCAC
The phase 3 POD1UM-303/InterAACT 2 study (NCT04472429) met its primary end point, with data demonstrating there was a significant progression-free survival (PFS) benefit with the addition of retifanlimab-dlwr (Zynyz) to carboplatin and paclitaxel vs …